Top Keywords: genscript, crispr, hot, sars cov, ivt, cov, easyedit, sars, sa, new, quatro, elisa, manufacturing, anti, annual results presentation, in singapore to, manufacturing facility in, all things considered, state of art, 2021 annual, things considered, manufacturing capability, up state, results presentation, manufacturing facility, double stranded, genome editing, goes viral, facility in, sets up, closed end, to strengthen, singapore to, annual results, of art, all things, Theres a total of 117 keywords.
StatisticsWe first found this page on 2020-05-31 23:26:01 +0000. It was last re-indexed on 2025-02-04 17:59:58 +0000 and with a fetch interval of 90 days it will be fetched again in 56 days on 2025-05-05 or soon thereafter. Last fetch returned code 200, OK, the current page state is ACTIVE. Traffic Data for www.genscript.com.cnTraffic data is only available for sites with a CashRank of $15 or better, an Alexa rank better than 100,000 or PageRank of 2 or more.If you are the owner of /www.genscript.com.cn and you want to remove this page from the search results, just use robots.txt Similar SitesDrug Discovery Archives - Plenge Gen @rplengePlenge Gen @rplengeDiscovery Research | Better Health
Human Genetics Archives - Plenge Gen @rplengePlenge Gen @rplengeDiscovery Research | Better Health
Plenge Gen @rplenge - Discovery Research | Better HealthPlenge Gen @rpDiscovery Research | Better Health
SARS-CoV-2 collection | EVAgVisit our page dedicated to antiviral compounds test results against SARS-CoV-2 Given the epidemiological situation concerning SARS-CoV-2, a simplified and faster procedure has been put in place for the supply of molecul
More sites similar to 金斯瑞-基因合成_引物合成_多肽合成_蛋白表达和抗体工程... Find Another Website
|
Sponsored Results Your Ad Here & Hundreds of Other ISEDN Engines & Directories- $3/Month or Less
Your Ad Here & Hundreds of Other ISEDN Engines & Directories- $3/Month or Less |
Copyright (C) 2007 - 2025 Text Ad King and SecretSearchEngineLabs.com. All Rights Reserved.
Terms and Conditions - Privacy Policy - Advertising - About Us - Login